Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Bausch Health
Deal Size : $413.0 million
Deal Type : Acquisition
Bausch Health Completes Acquisition of DURECT Corporation
Details : Through the acquisition, Basuch will leverage DURECT's lead asset, DUR-928 (Larsucosterol), is an epigenetic modulator. It is being evaluated for alcoholic hepatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $63.0 million
September 11, 2025
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Bausch Health
Deal Size : $413.0 million
Deal Type : Acquisition
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DURECT Announces Phase 3 Trial Design for Larsucosterol in Alcohol-Associated Hepatitis
Details : DUR-928 (larsucosterol) is an endogenous sulfated oxysterol and an epigenetic modulator, that inhibits DNA methylation. It is being evaluated for the treatment of alcohol-associated hepatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2024
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Breakthrough Therapy Status To DURECT's Larsucosterol For Hepatitis
Details : DUR-928 (larsucosterol) is an endogenous sulfated oxysterol and an epigenetic modulator, that inhibits DNA methylation. It is being evaluated for the treatment of alcohol-associated hepatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 21, 2024
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DUR-928 (larsucosterol), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2023
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DUR-928 (larsucosterol), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 07, 2023
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Cantor Fitzgerald
Deal Size : $10.0 million
Deal Type : Public Offering
DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants
Details : DUR-928 (larsucosterol), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 03, 2023
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Cantor Fitzgerald
Deal Size : $10.0 million
Deal Type : Public Offering
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial
Details : Larsucosterol (DUR-928) is an endogenous sulfated oxysterol and an epigenetic regulator. Epigenetic regulators are compounds that regulate patterns of gene expression without modifying the DNA sequence.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study comprised enrollment of 300 patients, with 100 patients in each arm for DUR-928 (larsucosterol), inhibits activity of DNMTs, epigenetic enzymes in AH Patients. Primary outcome measure is 90-day survival rate for patients treated with DUR-928 compar...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2022
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The potential of epigenetic regulator candidate, larsucosterol (also known as DUR-928) is to improve inflammation, cell death, and tissue regeneration in severe Alcohol-Associated Hepatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2021
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : National Institute on Alcohol Abuse and Alcoholism
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Larsucosterol (also known as DUR-928), the Company's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in AH patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 10, 2021
Lead Product(s) : Larsucosterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : National Institute on Alcohol Abuse and Alcoholism
Deal Size : Inapplicable
Deal Type : Inapplicable